诱导性多功能干细胞生产市场规模、份额及成长分析（依流程、工作流程、产品、应用、最终用途及地区）－2025-2032 年产业预测

诱导性多功能干细胞生产市场规模预计在 2023 年达到 15.3 亿美元，2024 年达到 16.8 亿美元，到 2032 年达到 34.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 9.6%。

干细胞（iPSC）製造市场在再生医学和细胞治疗领域正在经历显着的成长和创新。 iPSC 源自成体细胞并被重新编程为多功能状态，为个人化治疗和疾病建模提供了巨大潜力。这一快速增长的市场是由人们对 iPSC 在药物发现和各种疾病状况中的应用的理解不断加深所推动的。研发和生技公司正在积极开发可扩展、经济高效的 iPSC 生产技术。虽然学术界、工业界和医疗机构之间的合作正在推动进步，但严格的法律规范和道德考量正在塑造格局并凸显标准化方法的必要性。随着全球医疗保健的发展，iPS细胞製造市场将继续扩大，为科学突破和治疗解决方案铺路。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局

诱导性多功能干细胞生产市场规模（按流程和复合年增长率） (2025-2032)

• 市场概览
• 手动的
• 自动化

诱导性多功能干细胞生产市场规模（依工作流程和复合年增长率） (2025-2032)

• 市场概览
• 重新程式设计
• 细胞培养

诱导性多功能干细胞生产市场规模（按产品和复合年增长率） (2025-2032)

• 市场概览
• 耗材和套件
• 装置
• 服务

诱导性多功能干细胞生产市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 药物开发与发现
• 再生医学
• 毒理学研究
• 疾病模型
• 其他的

诱导性多功能干细胞生产市场规模（依最终用途和复合年增长率） (2025-2032)

• 市场概览
• 学术研究所
• 生物技术和製药公司
• 医院和诊所

诱导性多功能干细胞生产市场规模（依地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• FUJIFILM Cellular Dynamics（USA）
• Astellas Pharma（Japan）
• Thermo Fisher Scientific（USA）
• Takara Bio（Japan）
• Lonza Group（Switzerland）
• Merck KGaA（Germany）
• ReproCELL（Japan）
• STEMCELL Technologies（Canada）
• Fate Therapeutics（USA）
• Cynata Therapeutics（Australia）
• Axol Bioscience（UK）
• Ncardia（Belgium）
• Pluricell Biotech（Brazil）
• Evotec（Germany）
• BioTime（USA）
• Cellular Engineering Technologies（USA）
• StemoniX（USA）
• BrainXell（USA）
• EMD Millipore（USA）
• R&D Systems（USA）

结论和建议

Induced Pluripotent Stem Cells Production Market size was valued at USD 1.53 billion in 2023 and is poised to grow from USD 1.68 billion in 2024 to USD 3.49 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The triggered pluripotent stem cell (iPSC) manufacturing market is experiencing remarkable growth and innovation within regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed into a pluripotent state, iPSCs offer significant potential for personalized treatments and disease modeling. This burgeoning market is fueled by an increasing understanding of iPSCs' applications in drug discovery and various medical conditions. Researchers and biotech firms are actively developing efficient techniques for scalable and cost-effective iPSC production. Collaborations among academia, industry, and healthcare institutions are driving advancements, while stringent regulatory frameworks and ethical considerations shape the landscape, highlighting the need for standardized practices. As global healthcare evolves, the iPSC manufacturing market is set for continued expansion, paving the way for scientific breakthroughs and therapeutic solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Induced Pluripotent Stem Cells Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Induced Pluripotent Stem Cells Production Market Segments Analysis

Global Induced Pluripotent Stem Cells Production Market is segmented by Process, Workflow, Product, Application, End-Use and region. Based on Process, the market is segmented into Manual and Automated. Based on Workflow, the market is segmented into Reprogramming and Cell Culture. Based on Product, the market is segmented into Consumables & Kits, Instruments and Services. Based on Application, the market is segmented into Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, Disease Modeling and Others. Based on End-Use, the market is segmented into Academic & Research Institutes, Biotechnology & Pharmaceutical Companies and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Induced Pluripotent Stem Cells Production Market

A significant driving force behind the global induced pluripotent stem cells (iPSC) production market is the ongoing advancements in regenerative medicine. These stem cells present substantial potential for creating personalized and effective treatments for various medical conditions, thereby attracting significant investment in research and development. Such innovations not only broaden the applications of iPSCs but also present novel therapeutic options, which significantly propel market growth. The increasing interest from pharmaceutical companies and healthcare institutions further enhances this trend, underscoring the pivotal role that advancements in regenerative medicine play in fostering market expansion and stimulating continued investment in iPSC technologies.

Restraints in the Induced Pluripotent Stem Cells Production Market

One significant constraint facing the global induced pluripotent stem cells (iPSC) production market is the array of ethical and regulatory hurdles. Issues regarding the use of human-derived materials, coupled with concerns about the potential misuse of iPSC technology, have led to the implementation of strict regulations in various regions. These obstacles can impede research initiatives, raise compliance costs, and generate market uncertainty. Consequently, such factors can hinder the pace of iPSC adoption and commercialization, ultimately affecting the growth and development of this promising sector in regenerative medicine and biotechnology.

Market Trends of the Induced Pluripotent Stem Cells Production Market

The global Induced Pluripotent Stem Cells (iPSC) production market is witnessing a significant trend driven by the emergence of iPSC-based disease modeling. Researchers and pharmaceutical companies are increasingly leveraging iPSC technology to develop disease-specific cell lines, facilitating more accurate and personalized modeling of a variety of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular diseases. This shift not only enhances drug discovery and development processes but also fosters the emergence of targeted and effective therapeutic strategies, ultimately shaping the future landscape of precision medicine. As a result, the demand for iPSC products is expected to surge, propelling market growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Induced Pluripotent Stem Cells Production Market Size by Process & CAGR (2025-2032)

• Market Overview
• Manual
• Automated

Global Induced Pluripotent Stem Cells Production Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• Reprogramming
• Cell Culture

Global Induced Pluripotent Stem Cells Production Market Size by Product & CAGR (2025-2032)

• Market Overview
• Consumables & Kits
• Instruments
• Services

Global Induced Pluripotent Stem Cells Production Market Size by Application & CAGR (2025-2032)

• Market Overview
• Drug Development & Discovery
• Regenerative Medicine
• Toxicology Studies
• Disease Modeling
• Others

Global Induced Pluripotent Stem Cells Production Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

Global Induced Pluripotent Stem Cells Production Market Size & CAGR (2025-2032)

• North America (Process, Workflow, Product, Application, End-Use)
  • US
  • Canada
• Europe (Process, Workflow, Product, Application, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Process, Workflow, Product, Application, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Process, Workflow, Product, Application, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Process, Workflow, Product, Application, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• FUJIFILM Cellular Dynamics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReproCELL (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• STEMCELL Technologies (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cynata Therapeutics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axol Bioscience (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ncardia (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pluricell Biotech (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioTime (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellular Engineering Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• StemoniX (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BrainXell (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Millipore (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations